The University of Chicago Header Logo

Connection

Megan Mcnerney to Humans

This is a "connection" page, showing publications Megan Mcnerney has written about Humans.
Connection Strength

0.336
  1. Haploinsufficient Transcription Factors in Myeloid Neoplasms. Annu Rev Pathol. 2024 Jan 24; 19:571-598.
    View in: PubMed
    Score: 0.031
  2. The significance of CUX1 and chromosome 7 in myeloid malignancies. Curr Opin Hematol. 2022 03 01; 29(2):92-102.
    View in: PubMed
    Score: 0.028
  3. CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions. Leukemia. 2022 05; 36(5):1421-1425.
    View in: PubMed
    Score: 0.028
  4. Genomic studies controvert the existence of the CUX1 p75 isoform. Sci Rep. 2022 01 07; 12(1):151.
    View in: PubMed
    Score: 0.028
  5. The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell. 2018 11 01; 23(5):634-635.
    View in: PubMed
    Score: 0.022
  6. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697.
    View in: PubMed
    Score: 0.021
  7. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527.
    View in: PubMed
    Score: 0.020
  8. The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Res. 2017 Jun 20; 45(11):6350-6361.
    View in: PubMed
    Score: 0.020
  9. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). Br J Haematol. 2014 Aug; 166(4):550-6.
    View in: PubMed
    Score: 0.016
  10. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013 Feb 07; 121(6):975-83.
    View in: PubMed
    Score: 0.015
  11. Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfus. 2010 Apr; 8(2):126-8.
    View in: PubMed
    Score: 0.012
  12. The CD2 family of natural killer cell receptors. Curr Top Microbiol Immunol. 2006; 298:91-120.
    View in: PubMed
    Score: 0.009
  13. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005 May; 5(5):363-74.
    View in: PubMed
    Score: 0.009
  14. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol Immunol. 2005 Feb; 42(4):489-94.
    View in: PubMed
    Score: 0.009
  15. Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol. 2023 02; 200(4):489-493.
    View in: PubMed
    Score: 0.007
  16. EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy. Exp Hematol. 2022 11; 115:54-67.
    View in: PubMed
    Score: 0.007
  17. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021 10 27; 12(11):1005.
    View in: PubMed
    Score: 0.007
  18. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
    View in: PubMed
    Score: 0.006
  19. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management. J Mol Diagn. 2018 07; 20(4):522-532.
    View in: PubMed
    Score: 0.005
  20. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 2017 03; 13(3):e1006589.
    View in: PubMed
    Score: 0.005
  21. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 01; 19(1):43-56.
    View in: PubMed
    Score: 0.005
  22. Widespread genetic epistasis among cancer genes. Nat Commun. 2014 Nov 19; 5:4828.
    View in: PubMed
    Score: 0.004
  23. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene. 2015 May 21; 34(21):2807-13.
    View in: PubMed
    Score: 0.004
  24. Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. J Am Med Inform Assoc. 2014 Nov-Dec; 21(6):969-75.
    View in: PubMed
    Score: 0.004
  25. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013 Sep; 3(9):993-1001.
    View in: PubMed
    Score: 0.004
  26. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33.
    View in: PubMed
    Score: 0.004
  27. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.003
  28. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol. 2000 Dec 01; 165(11):6627-34.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.